What is QGenda doing strategically?

QGenda completed the acquisition of New Innovations on July 9, 2025. New Innovations is the largest provider of residency management software in the US, used by hospitals and health systems to manage all aspects of physician graduate medical education programs.

Academic medical centers and teaching hospitals are a high-value, sticky segment. By owning residency management alongside scheduling and credentialing, QGenda can now control the full provider lifecycle from trainee onboarding through attending deployment in a single platform. No credible direct competitor owns that scope today. It also creates a long-term lock-in mechanism: AMC contracts that span GME, credentialing, and scheduling are structurally difficult to replace without major operational disruption.

This is the most strategically significant move QGenda has made in the past 12 months. The GME market is compliance-heavy and relationship-driven, which means stickiness is high and displacement costs are enormous. Competitors without a GME answer will lose AMC evaluations to QGenda on scope alone.

QGenda published results of a commissioned Forrester Total Economic Impact study in January 2026. The study claims a 430% ROI over three years, $22.3 million in reduced labor costs, and $6.9 million in increased profit for a composite health system.

Healthcare CIOs and CFOs are under sustained pressure to justify technology spend. A Forrester-branded ROI number short-circuits the feature-level evaluation and puts QGenda into a financial justification conversation where most point-solution competitors cannot produce equivalent proof. It also makes QGenda easier for internal champions to sell upward in a health system's budget cycle.

This is a deliberate sales motion, not a brand exercise. Expect QGenda to lead with this number in enterprise renewals and competitive displacements throughout 2026. Any competitor without third-party financial validation is now at a structural disadvantage in late-stage deals.

Multiple public reviews on Google Play, G2, and Capterra in late 2025 and early 2026 report recurring app instability after a software update, forced re-authentication on every session break, and clunky day-view navigation. QGenda's own support responses acknowledge the issues are unresolved.

Frontline nurses and physicians are the daily users of the mobile app. If they find it frustrating, clinical department heads and CNOs hear about it. For any competitor with a genuinely polished mobile-first experience, this is a concrete talking point in competitive evaluations, particularly in nurse scheduling where QGenda is pushing hard for growth.

This is an active known issue, not a historic complaint. It does not threaten QGenda's enterprise contracts in the near term, but it is a real opening for a competitor who can demonstrate mobile experience superiority to the clinical buyer.